Once-promising HDL-targeted therapy fails to show plaque regression
Trial stopped early after evacetrapib fails to budge event rate
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy